Developing Novel Dual Payload ADCs With Tailored Mechanistic Combinations to Address Diverse Clinical Challenges

• Introducing a pipeline of bispecific, dual payload ADCs combining multi-targeting and mechanistic innovations
• Contextualizing dual payload strategies combining Topo1 with an orthogonal or synergistic MoA to combat diverse resistance mechanisms
• Breaking down preclinical efficacy and safety data of dual payload programs and highlighting future clinical development plans

Speakers:

Shude Yan

Chief Scientific Officer

Hangzhou DAC Biotech Co. Ltd.